Smart Immune and Greater Paris University Hospitals (AP-HP) begin groundbreaking Phase I/II trial with ProTcellTM, a thymus-empowered T-cell therapy…
stemadminStem Cell ResearchNo comments

Smart Immune Smart Immune and Greater Paris University Hospitals (AP-HP) begin groundbreaking Phase I/II trial with ProTcellTM, a thymus-empowered T-cell therapy platform, in adults with blood cancers First trial to inject T cell progenitor cells derived from cord blood using Smart Immunes ProTcellTM platform PARIS, France, October 13, 2022 Smart Immune SAS, a clinical-stage biotechnology company developing ProTcell, a thymus-empowered T-cell therapy platform to fully and rapidly re-arm the immune system, and the Greater Paris University Hospitals (AP-HP), announced today that SMART102, a human T-lymphoid progenitor cell injection derived from cord blood using Smart Immunes ProTcell platform, has entered clinical testing in a trial sponsored and led by Great Paris University Hospitals (AP-HP). The multicenter Phase I/II trial (NCT04707300) is a proof-of-concept, dose escalation, 10-patient study that will evaluate safety and efficacy of SMART102 to accelerate immune reconstitution after allogeneic hematopoietic stem cell transplantation (HSCT) in adult patients with hematological malignancies. SMART102 is an injection into the patient of allogeneic T-cell progenitors produced by Smart Immunes ProTcell platform designed to travel to the patients thymus and become differentiated into fully functional T-cells. The trial has been designed to assess the potential of the ProTcell technology to improve clinical outcomes of HSCT. Overall survival in this patient group is currently low at 5 years post-HSCT, with around 50% mortality1

Read more
Celebrating 20 years of discovery, Picower Institute looks ahead to continuing impact – MIT News
stemadminStem Cell ResearchNo comments

If ever there was an event that would seem designed for dwelling on the past, it would be the anniversary celebration of an institute centered on the study of memory, but the first of many insights offered by the 20th Anniversary Exhibition of The Picower Institute for Learning and Memory at MIT Sept. 22 was that memory is all about the future. Ever since University of California at Berkeley psychology professor David Foster was a postdoc in the Picower Institute lab of Fairchild Professor Matthew Wilson, his research has employed sophisticated neural recordings and behavioral experiments showing that animals dont just store memories of the spaces and objects around them. In the first talk of the day, Foster demonstrated that during periods of rest animals often think about where they might want to go and rehearse possible future routes in their mind.

Read more
A $7 million grant to grow stem cell research – Swinburne University of Technology
stemadminStem Cell ResearchNo comments

Swinburne University of Technology has received a share of a $7 million Medical Research Future Fund grant to develop first-of-its-kind Australian research to allow live stem cells to be 3D printed and used in treatments. The cross-institutional research team will develop novel cartilage-based stem cell therapies that will change the way we care for people living with painful joint disease, such as osteoarthritis, and facial disfigurement. More than two million Australians live with the painful and degenerative joint disease, osteoarthritis, and one in 2,000 newborns are born with microtia an absent or poorly formed ear which can lead to hearing loss, speech and literacy delays. This research could actually restore damaged or absent cartilage, transforming how these conditions are treated and vastly improving quality of life for sufferers

Read more
Pluristyx, panCELLa, and Implant Therapeutics Announce Definitive Merger Agreement – Business Wire
stemadminStem Cell ResearchNo comments

SEATTLE--(BUSINESS WIRE)--Today, Pluristyx, panCELLa, and Implant Therapeutics management are excited to announce their corporate merger, pending shareholder approval. The merged company will combine complementary portfolios to offer end-to-end customer support and provide increased access to a wide range of induced pluripotent stem cell (iPSC)-related products and services.

Read more
Genetics: the Vatican Does Not Intend to Be Behind the Times – FSSPX.News
stemadminStem Cell ResearchNo comments

The Holy See has just organized an unprecedented symposium on molecular and cellular engineering. The goal: to keep control of a constantly evolving science, which requires the development and updating of solid ethical safeguards for scientists. This science is rolling; the train is moving. But instead of lamenting over this, we need to take the initiative and hop on that train, intervene, and, if needed, divert it onto another track, said Ralf Stutzki, head of the ethics Molecular Systems Engineering at the National Center of Competence in Research at the University of Basel, Switzerland.

Read more
Personhood Lawsuit Before the Supreme Court? – Daily Kos
stemadminStem Cell ResearchNo comments

A lawsuit to the United States Supreme Court is being brought by two pregnant people in Rhode Island, on behalf of their unborn children. Will it be considered? The pliaintiffs wish the Court to define personhood. Personhood is an opinion: that a fetus, embryo or blastocyst (fertilized human egg) must be treated as a person with full rights and protections under law. Briefly, the plaintiffs (below) applied to the Rhode Island Supreme Court and were denied, apparently on the basis of Roe v

Read more
Outlook on the Cell Therapy Global Market to 2028 – Increased Demand for Novel, Better Medicines for Diseases Such as Cancer and CVD Has Resulted in…
stemadminStem Cell ResearchNo comments

Dublin, Oct. 05, 2022 (GLOBE NEWSWIRE) -- The "Global Cell Therapy Market, By Use Type, By Therapy Type, By Product, By Technology & By Region- Forecast and Analysis 2022-2028" report has been added to ResearchAndMarkets.com's offering. The Global Cell Therapy Market was valued at USD 14.86 Billion in 2021, and it is expected to reach a value of USD 35.95 Billion by 2028, at a CAGR of 13.45% over the forecast period (2022 - 2028). The cell therapy industry is being propelled forward by an increase in the number of clinical trials for cell-based treatments

Read more

Theme: Illdy.